Replies to post #243587 on Biotech Values

[dewophile]

This is in line w the JNJ data from a pretty large phase 2 that showed 80 percent efficacy for severe disease and 70 for milder lower respiratory tract disease.
Gsk never gave a point estimate except to say their data is “exceptional”. I don’t know if it’s still exceptional in light of the PFE data

[DewDiligence]

PFE slides for today’s RSV/COVID investor CC:

https://s28.q4cdn.com/781576035/files/doc_downloads/2022/10/IDWeek22/IDWeek-2022-investor-call_FINAL.pdf

The (impressive) safety profile of the RSV vaccine is shown on slides 12-13.